Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Vainchenker, William  [Clear All Filters]
2023
Rodriguez-Meira A, Norfo R, Wen S, Chédeville AL, Rahman H, O'Sullivan J, Wang G, Louka E, Kretzschmar WW, Paterson A, et al. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution. Nat Genet. 2023.
Willekens C, Laplane L, Dagher T, Benlabiod C, Papadopoulos N, Lacout C, Rameau P, Catelain C, Alfaro A, Edmond V, et al. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice. Leukemia. 2023.
2022
Murakami S, Barroca V, Perié L, Bravard A, Bernardino-Sgherri J, Tisserand A, Devanand C, Edmond V, Magniez A, Bento STenreira, et al. In vivo monitoring of Polycythemia Vera development reveals carbonic anhydrase 1 as a potent therapeutic target. Blood Cancer Discov. 2022.
2021
Mosca M, Hermange G, Tisserand A, Noble RJohn, Marzac C, Marty C, Le Sueur C, Campario H, Vertenoeil G, El-Khoury M, et al. Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms. Blood. 2021.
2016
Abdelouahab H, Zhang Y, Wittner M, Oishi S, Fujii N, Besancenot R, Plo I, Ribrag V, Solary E, Vainchenker W, et al. CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. Oncotarget. 2016.
2015
Debeurme F, Lacout C, Moratal C, Bagley RG, Vainchenker W, Adrian F, Villeval J-L. JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice. J Cell Mol Med. 2015.
2013
Saliba J, Hamidi S, Lenglet G, Langlois T, Yin J, Cabagnols X, Secardin L, Legrand C, Galy A, Opolon P, et al. Heterozygous and Homozygous JAK2(V617F) States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients. PLoS One. 2013;8(9):e74257.